Yihan Wang

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

Thomas O’Hare, William C. Shakespeare, Xiaotian Zhu et al. · Cancer Cell · 2009 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +9

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

Wei‐Sheng Huang, Shuangying Liu, Dong Zou et al. · Journal of Medicinal Chemistry · 2016 · 404 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

Sen Zhang, Rana Anjum, Rachel M. Squillace et al. · Clinical Cancer Research · 2016 · 326 citations · Full text

Medicine, Oncology, Pharmacology +15

Characterization of Susceptibility of Inbred Mouse Strains to Diabetic Nephropathy

Zhonghua Qi, Hiroki Fujita, Jianping Jin et al. · Diabetes · 2005 · 300 citations · Full text

Medicine, Nephrology, Pathology +17

Structural Mechanism of the Pan‐BCR‐ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance

Tianjun Zhou, Lois Commodore, Wei‐Sheng Huang et al. · Chemical Biology & Drug Design · 2010 · 284 citations

Medicine, Oncology, Pharmacology +14